Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America

Posted on by sHq_LoGiNz

MILAN & HYOGO, Japan–(BUSINESS WIRE)–Italfarmaco and JCR announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.